Clinical Trials on High Risk Percutaneous Coronary Intervention in Singapore

Total 6 results

National Heart Centre Singapore

Unknown

Plaque mOrphology iMpact on Side Branch Occlusion at oPtical Coherence Tomography Evaluation in Percutaneous Coronary Interventions (POMPEI)

Percutaneous Coronary Intervention | Bifurcation

Singapore
Boehringer Ingelheim

Completed

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

Canada, United States, Spain, Korea, Republic of, Australia, Germany, Taiwan, Hong Kong, Thailand, United Kingdom, Turkey, Netherlands, Ireland, Hungary, Croatia, Colombia, Israel, Singapore, Italy, New Zealand, Greece, Mexico, Norway, Swed... and more
ECRI bv
University of Bern; European Cardiovascular Research Center; Terumo Medical Corporation and other collaborators

Completed

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen (MASTER DAPT)

Coronary Artery Disease | PCI | High Bleeding Risk

Netherlands, France, United Kingdom, Australia, Singapore, Japan, Italy, Poland, Spain, Switzerland, Israel, Argentina, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, India, Korea, Republic... and more
Brigham and Women's Hospital
National Institute of Mental Health (NIMH); Yale University; Orygen

Recruiting

AMP SCZ® Observational Study: PREDICT-DPACC (AMP SCZ)

Psychosis | Remission | Conversion | Clinical High Risk

United States, United Kingdom, Canada, Italy, Australia, Chile, China, Denmark, Germany, Hong Kong, Korea, Republic of, Singapore, Spain, Switzerland
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States

Clinical Trials on High Risk Percutaneous Coronary Intervention in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations